Business news from Ukraine


The share of public procurement of medicines in January-March 2019 totaled 20% of the Ukrainian pharmaceutical market, SMD consulting company (Kyiv) has said after studying the Ukrainian pharmaceutical market.
According to the company, in January-March 2019, budget medical procurement in monetary terms increased 40% compared to the same period of 2018 in the centralized procurement segment and by 19% in the procurement segment of medical institutions.
In addition, budget procurement in kind increased 134% in the segment of centralized procurement and by 13% in procurement by hospitals.
At the same time, the company said that in the first quarter of 2019, hospitals, in accordance with their needs, used the ending stocks of the 2018 budget funds to purchase drugs and expensive medicines.
In general, in the first quarter of 2019, the pharmaceutical market of Ukraine grew by 11% in monetary terms compared to the same period of 2018, to UAH 13 billion, while in kind it fell by 7%, to 177 million packages.
At the same time, according to the analysts of the company, the prescription segment in the first quarter of 2019 grew by 17% in monetary terms and decreased 1% in physical terms.
In addition, in the first quarter of 2019, sales of foreign manufacturers in kind decreased 5%, while sales of Ukrainian pharmaceutical manufacturers decreased 8%.

, ,


Biopharma, a blood products maker, plans to boost suppliers of its products to the traditional markets for the company and actively develop new ones – India, African countries, Biopharma Group President Kostiantyn Yefymenko has said in an interview with Interfax-Ukraine. The group plans to boost sales in Ukraine and supplies to Belarus, Kazakhstan, Uzbekistan, Azerbaijan, Armenia, Tajikistan, Kyrgyzstan and Georgia.
“At the same time, the most promising for us is the Indian market, and after it – Africa, where we will intensively increase our presence,” Yefymenko said.
Commenting on plans for expansion of activities in foreign pharmaceutical markets, he said that currently Biopharma “does not strongly focus on the EU countries” because of the conservatism of this market, although it delivers its drugs, in particular probiotics, to some European countries – Slovakia and the Czech Republic.
Biopharma is one of the ten largest Ukrainian producers of medicines. It produces more than 20 immunobiological preparations from donor blood, preparations obtained by recombinant DNA technology and probiotics.

, , ,